The Myelofibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Myelofibrosis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myelofibrosis Market.
Some of the key takeaways from the Myelofibrosis Pipeline Report:
- Companies across the globe are diligently working toward developing novel Myelofibrosis treatment therapies with a considerable amount of success over the years.
- Myelofibrosis companies working in the treatment market are Active Biotech, Hinova Pharmaceuticals, AbbVie, iOnctura, Sumitomo Pharma Oncology, Pharmaxis, Keros Therapeutics, Nippon Shinyaku, Incyte Corporation, MorphoSys, Geron Corporation, and others, are developing therapies for the Myelofibrosis treatment
- Emerging Myelofibrosis therapies in the different phases of clinical trials are- Tasquinimod, HC-X027, ABBV-744, IOA-244, TP-3654, PXS-5505, KER-050, NS-018, Parsaclisib, Pelabresib, Imetelstat, and others are expected to have a significant impact on the Myelofibrosis market in the coming years.
- In June 2022, New findings from Cohort 3 of AbbVie’s Phase II REFINE study of experimental navitoclax combined with ruxolitinib in patients with myelofibrosis (MF), a rare and challenging to treat blood malignancy, were released. These findings confirmed the value of early myelofibrosis management and the possibility of better clinical outcomes
- In February 2022, With regard to patents covering the use of tasquinimod and other S100 inhibitors for the treatment of myelofibrosis, Active Biotech entered into an exclusive license arrangement with Oncode Institute in the Netherlands
- In April 2021, Imetelstat (GRN163L), a drug for the treatment of intermediate-2 or high-risk myelofibrosis (MF), is being compared to best available therapy (BAT) in a randomized open-label, Phase III research started by Geron Corporation
- In September 2019, For the treatment of adult patients with Intermediate-2 or High-risk myelofibrosis (MF) whose disease has relapsed after or is resistant to janus kinase (JAK) inhibitor treatment, or relapsed/refractory MF, the United States Food and Drug Administration (FDA) has granted imimetestat Fast Track designation
Myelofibrosis Overview
A rare condition called myelofibrosis causes the normal bone marrow tissue to eventually be replaced by a fibrous, scar-like substance.It is categorized as a particular form of chronic leukemia and is a member of the myeloproliferative diseases family of blood diseases.This eventually results in progressive bone marrow failure.
Get a Free Sample PDF Report to know more about Myelofibrosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/myelofibrosis-pipeline-insight
Emerging Myelofibrosis Drugs Under Different Phases of Clinical Development Include:
- Tasquinimod: Active Biotech
- HC-X027: Hinova Pharmaceuticals
- ABBV-744: AbbVie
- IOA-244: iOnctura
- TP-3654: Sumitomo Pharma Oncology
- PXS-5505: Pharmaxis
- KER-050: Keros Therapeutics
- NS-018: Nippon Shinyaku
- Parsaclisib: Incyte Corporation
- Pelabresib: MorphoSys
- Imetelstat: Geron Corporation
Route of Administration
Myelofibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
Molecule Type
Products have been categorized under various Molecule types, such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Myelofibrosis Pipeline Therapeutics Assessment
- Myelofibrosis Assessment by Product Type
- Myelofibrosis By Stage and Product Type
- Myelofibrosis Assessment by Route of Administration
- Myelofibrosis By Stage and Route of Administration
- Myelofibrosis Assessment by Molecule Type
- Myelofibrosis by Stage and Molecule Type
DelveInsight’s Myelofibrosis Report covers around 45+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Myelofibrosis product details are provided in the report. Download the Myelofibrosis pipeline report to learn more about the emerging Myelofibrosis therapies
Some of the key companies in the Myelofibrosis Therapeutics Market include:
Key companies developing therapies for Myelofibrosis are – Nippon Shinyaku, Kartos Therapeutics, Sumitomo Pharma Oncology, Pharmaxis, MorphoSys, Merck & Co, AbbVie, Suzhou Zelgen Biopharmaceuticals, Geron Corporation, Keros Therapeutics, Galecto, Telios Pharma, Chia Tai Tianqing Pharmaceutical Group, Imago BioSciences, Roche, Incyte Corporation, Disc Medicine, Inc, Bristol-Myers Squibb, Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Cellenkos, Jacobio Pharmaceuticals, Active Biotech, Actuate Therapeutics, Samus Therapeutics, Karyopharm Therapeutics, and others.
Myelofibrosis Pipeline Analysis:
The Myelofibrosis pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Myelofibrosis with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myelofibrosis Treatment.
- Myelofibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Myelofibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myelofibrosis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Myelofibrosis drugs and therapies
Myelofibrosis Pipeline Market Drivers
- Increase in R&D for the development of new and effective drug for the treatment, increasing Incidence in Elderly Population, development of biological therapies or immunotherapies are some of the important factors that are fueling the Myelofibrosis Market.
Myelofibrosis Pipeline Market Barriers
- However, side effects associated with the drugs, high cost of therapy and other factors are creating obstacles in the Myelofibrosis Market growth.
Scope of Myelofibrosis Pipeline Drug Insight
- Coverage: Global
- Key Myelofibrosis Companies: Active Biotech, Hinova Pharmaceuticals, AbbVie, iOnctura, Sumitomo Pharma Oncology, Pharmaxis, Keros Therapeutics, Nippon Shinyaku, Incyte Corporation, MorphoSys, Geron Corporation, and others
- Key Myelofibrosis Therapies: Tasquinimod, HC-X027, ABBV-744, IOA-244, TP-3654, PXS-5505, KER-050, NS-018, Parsaclisib, Pelabresib, Imetelstat, and others
- Myelofibrosis Therapeutic Assessment: Myelofibrosis current marketed and Myelofibrosis emerging therapies
- Myelofibrosis Market Dynamics: Myelofibrosis market drivers and Myelofibrosis market barriers
Request for Sample PDF Report for Myelofibrosis Pipeline Assessment and clinical trials
Table of Contents
|
1 |
Myelofibrosis Report Introduction |
|
2 |
Myelofibrosis Executive Summary |
|
3 |
Myelofibrosis Overview |
|
4 |
Myelofibrosis- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Myelofibrosis Pipeline Therapeutics |
|
6 |
Myelofibrosis Late Stage Products (Phase II/III) |
|
7 |
Myelofibrosis Mid Stage Products (Phase II) |
|
8 |
Myelofibrosis Early Stage Products (Phase I) |
|
9 |
Myelofibrosis Preclinical Stage Products |
|
10 |
Myelofibrosis Therapeutics Assessment |
|
11 |
Myelofibrosis Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Myelofibrosis Key Companies |
|
14 |
Myelofibrosis Key Products |
|
15 |
Myelofibrosis Unmet Needs |
|
16 |
Myelofibrosis Market Drivers and Barriers |
|
17 |
Myelofibrosis Future Perspectives and Conclusion |
|
18 |
Myelofibrosis Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services